Treatment with the T-cell immunotherapy Orca-T improved survival free of moderate-to-severe chronic graft-versus-host disease ...
Signal12, Inc. (Signal12), a clinical-stage ophthalmic pharmaceutical company focused on first-of-a-kind patented technologies that enable existing drugs to act through unique neural pathways, today ...
Signal12, Inc. (Signal12), a clinical-stage ophthalmic pharmaceutical company focused on first-of-a-kind patented technologies that enable existing drugs to act through unique neural pathways, today ...
GlobalData on MSN12h
Orca Bio makes a splash as T-cell therapy cuts GvHD in blood cancer patientsGraft versus host disease (GvHD) is a complication from stem cell transplants where the patient recognises the cells as foreign and rejects them.
Despite the Trump administration's shake-up of the agency, the US FDA is the first port of call for most ASX biotechs.
"I thought there could be a better way to install a micro bright light into a low-water, fountain," said an inventor, from Peoria, Ariz., "so I invented THE NEPTUNE MOUNT. My design enables you to ...
Dealbreaker on MSN7h
AstraZeneca Aims to Make Cell Therapy More Accessible With $425M EsoBiotec AcquisitionAstraZeneca’s EsoBiotec acquisition is the latest in a series of deals struck by the pharma giant to secure a place in the next wave of cell therapies for cancer and immune-mediated diseases.
In terms of response, it met its primary end point in all 3 doses. 1 The ORR was 50% or higher [in all 3 groups]. The dose of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback